China Pharma Holdings (CPHI) Fundamental Analysis: Revenue, Earnings & Valuation

2.94 / 10

Underperform

Fundamental rating is Underperform with a 2.9/10 score. Inventory turnover (1.63) and interest coverage (15.6) are strengths, but revenue YoY falls –14% and current liabilities represent 88% of total liabilities, indicating pressure. Overall fundamentals are weak.

Analysis Checks(3/10)

Revenue-MV

Value-0.96

Score2/3

Weight72.20%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value-14.04

Score1/3

Weight-4.46%

1M Return-0.38%

Inventory turnover ratio

Value1.63

Score3/3

Weight-11.18%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value88.41

Score1/3

Weight-18.16%

1M Return-1.69%

PB-ROE

Value-0.66

Score1/3

Weight91.98%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value26.96

Score0/3

Weight-49.45%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-13.19%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-14.04

Score1/3

Weight-3.50%

1M Return-0.30%

Cost of sales ratio (%)

Value109.69

Score1/3

Weight-67.08%

1M Return-7.95%

Asset-MV

Value-0.49

Score1/3

Weight102.84%

1M Return6.31%

Is CPHI undervalued or overvalued?

CPHI scores 2.94/10 on fundamentals and holds a Premium valuation at present. Backed by its -24.47% ROE, -76.91% net margin, -1.01 P/E ratio, 0.39 P/B ratio, and 72.69% earnings growth, these metrics solidify its Underperform investment rating.